AnnouncementsZydus receives final approval for Telmisartan Tablets
No recommendations so far.What's your call on Cadila Health today?
|Company Name||Last Price||%
|Dr Reddys Labs||3212.20||-0.19||3240.00||2420.00||54,724.91|
|Mar' 14||Dec' 13||Sep' 13||Jun' 13|
|Scheme||No. of Shares|
|Reliance Pharma Fund (G)||753,552|
|Franklin India Bluechip Fund (G)||667,058|
|Reliance Equity Opportunities Fund - Retail Plan (G)||623,194|
|SBI Magnum Tax Gain Scheme (G)||558,019|
Vaibhav Global Recommended on Jun 11th 2014
Recommended price 675.00 | Peak from reco 975.00 44.44%
What are Multi baggers?
Our experts panel will help you to get you those life-changing stocks, tomorrow's bluechips today.
Cadila Health is in the Pharmaceuticals sector. The current market capitalisation stands at Rs 26,320.42 crore.The company has reported a consolidated sales of Rs 2,020.38 crore and a Net Profit of Rs 247.12 crore for the quarter ended Jun 2014.
The company management includes Pankaj R Patel - Chairman & Managing Director, Sharvil P Patel - Deputy Managing Director, Humayun Dhanrajgir - Director, Mukesh M Patel - Director, Nitin R Desai - Director, Apurva S Diwanji - Director, Dharmishta N Rawal - Additional Director.
It is listed on the BSE with a BSE Code of 532321 and the NSE with an NSE Code of CADILAHC.
Its Registered office is at "Zydus Tower", Satellite Cross Roads,,Sarkhej Gandhinagar Highway Ahmedabad,Gujarat - 380015.
Their Registrars are Sharepro Services (India) Pvt.Ltd.